Work

Abstract CT258: A randomized, open-label, phase 3 study of fulvestrant and CDK4/6 inhibitors with or without gedatolisib as first-line treatment in patients with HR+/HER2- advanced breast cancer (VIKTORIA-2)

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct258

Authors: Sara Hurvitz, Barbara Pistilli, Virginia Kaklamani, Rachel M. Layman, Javier Cortés, Kyong Hwa Park, Massimo Cristofanilli, Brian Sullivan, Elizabeth C. Moser, Igor Gorbatchevsky, Giuseppe Curigliano

Institutions: Fred Hutch Cancer Center, Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center, Hospital Quirónsalud Barcelona, IDCQ Hospitales y Sanidad, S.L.U., Korea University Anam Hospital, Weill Cornell Medicine, University of Milan, European Institute of Oncology

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409821701

Cites:

Cited by: 1

Related to: 10